Cancer Immunology, Epigenetics, Leukemia, Lymphoma, Molecular Oncology, Myelodysplasia, Myeloma, Thrombotic thrombocytopenic purpura, cMYC

Development of single and mixed isoform selectivity PI3Kδ inhibitors by targeting Asn836 of PI3Kδ Miller, M. S., Mountford, S., Pinson, J. A., Zheng, Z., Künzli, M., Patel, V., Hogg, S. J., Shortt, J., Jennings, I. G. & Thompson, P. E. 1 Oct 2016 In : Bioorganic & Medicinal Chemistry Letters. 26, 19, p. 4790-4794 5 p. Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model Waldeck, K., Cullinane, C., Ardley, K., Shortt, J., Martin, B., Tothill, R. W., Li, J., Johnstone, R. W., McArthur, G. A., Hicks, R. J. & Wood, P. J. 1 Jul 2016 In : International Journal of Cancer. 139, 1, p. 194-204 11 p. The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock West, A. C., Martin, B. P., Andrews, D. A., Hogg, S. J., Banerjee, A., Grigoriadis, G., Johnstone, R. W. & Shortt, J. 4 Apr 2016 In : Oncogenesis. 5, 6 p., e216 Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma Fedele, P. L., Gregory, G. P., Gilbertson, M., Shortt, J., Kumar, B., Opat, S. & Grigoriadis, G. 1 Mar 2016 In : Annals of Hematology. 95, 4, p. 667-668 2 p. The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid Leukemia Baker, A., Gregory, G. P., Verbrugge, I., Kats, L., Hilton, J. J., Vidacs, E., Lee, E. M., Lock, R. B., Zuber, J., Shortt, J. & Johnstone, R. W. 1 Mar 2016 In : Cancer Research. 76, 5, p. 1158-1169 12 p.